Healthcare M&A activity spans pharmaceuticals, biotechnology, medical devices, and healthcare services. The sector attracts both strategic consolidators seeking scale and private equity investors focused on platform building in specialized segments.
Dutch biotech TargED Biopharmaceuticals has secured EUR 21.5 million in fresh funding from a syndicate of European life sciences investors to push its targeted approach to thrombotic diseases forward.
Keensight-backed inhalation API specialist Inke has acquired Pharmanoid, a manufacturing site focused on ophthalmic highly potent APIs, extending the platform beyond respiratory into adjacent therapeutic areas.
BioNTech has completed its acquisition of CureVac after 86.75% of shares were tendered, consolidating two German mRNA pioneers. The all-stock transaction sharpens BioNTech’s oncology focus and clears a long-running IP overhang.
Swiss precision oncology biotech FoRx Therapeutics has secured a EUR 50 million Series A led by repeat backers EQT Life Sciences, Novartis Venture Fund and Pfizer Ventures, with M Ventures participating. Proceeds fund Phase I development of lead asset FORX-428 with data expected by mid-2026.
MidEuropa has acquired a majority stake in MBL Group, a European CDMO for assisted mobility, rehabilitation and aged care equipment. Terms were not disclosed; the Lauritsen family reinvested and management remains in place.
Swiss healthcare startup Liom has secured EUR 13.9 million in funding from Red Bull Ventures and individual investors. The round backs its wearable glucose monitoring technology as the category draws increasing capital and scrutiny.
German healthtech startup Amplifold has closed an oversubscribed EUR 5 million seed round led by Matterwave Ventures and XISTA Science Ventures to advance DNA origami-based signal amplification for rapid tests.
Sweden’s Melt&Marble has closed a EUR 7.3 million Series A led by Industrifonden, with EIC Fund, Beiersdorf and Valio participating, to scale precision-fermented fats for personal care and food.
Belgian biotech Bioxodes raised EUR 5.5 million in a Series A extension with Newton Biocapital participating, taking its Series A to EUR 17.5 million as it prepares for a pivotal ICH trial.
UK gene therapy start-up EpilepsyGTx has raised EUR 31.75 million in Series A funding from XGEN Venture, the British Business Bank and a global biopharma to take EPY201 into Phase 1/2a trials for focal refractory epilepsy.
Great Point Partners has acquired a majority stake in Slovenia-based Lenis Group, a regional commercialization and distribution partner for niche and specialty prescription medicines across Central and Eastern Europe.
University of Leeds spinout IVFmicro has secured EUR 2.76 million to validate its microfluidic embryo-culture platform in fertility clinics, pushing toward human embryo trials.
Main has invested an undisclosed amount in Polypoint, a healthcare workforce management specialist. The funding underscores steady investor appetite for operational software tied to staffing intensity in care delivery.
London-based Punto Health has raised EUR 2.3 million in a seed round co-led by Shilling VC and Plus Partners to scale its AI-enabled dementia care platform and expand across the UK and Spain.
Aukera Therapeutics has raised CHF 4.5m (EUR 4.76m), bringing Zürcher Kantonalbank and seasoned biotech operator David Urech into an early-stage AI-enabled mTORC1 programme—an unusual show of risk appetite in today’s funding market.
London-based Hello Vet has raised EUR 17 million in Series A funding from Addition and Future Positive to expand its owner-inclusive veterinary clinic model across the UK and hire 200 clinicians.
UK healthcare company Relation has secured EUR 24.7 million in additional financing from NVentures, DCVC and Magnetic Ventures, underscoring sustained investor appetite for mid-market healthtech rounds.
Hello Vet’s EUR 11.81m Series A backs a tech-enabled, clinician-first veterinary model, signalling that wellbeing and workflow efficiency are now core to Europe’s animal health investment thesis.
Swiss biotech Allegria Therapeutics raises EUR 4.85m in a seed extension from ALK Abelló and specialist investors, underscoring sustained appetite for early-stage European healthcare plays.
Cycle Pharmaceuticals is acquiring US-based Applied Therapeutics in an all-cash deal, adding late-stage rare disease assets and expanding its metabolic and CNS pipeline.